Quidel Sofia莱姆病荧光免疫分析作为改良两步法一线试验的评估
本研究评估Quidel Sofia莱姆病荧光免疫分析在改良两步检测(MTTT)算法中作为一线试验的性能,并与Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM试验后接Zeus单价IgM/IgG确认试验进行比较。结果显示阳性符合率为91.4%(95% CI,77.6%-97.0%),阴性符合率为100%(95% CI,94.0%-100%),总体符合率为98.3%(95% CI,94.2%-99.4%),κ=0.945,表明几乎完全一致。
要点
- Sofia莱姆病试验作为一线试验与Zeus MTTT的阳性符合率为91.4%。
- 阴性符合率为100%,总体符合率为98.3%,κ=0.945。
- Sofia试验性能与FDA批准的MTTT相比表现良好。
核心结论
- Sofia莱姆病试验与FDA批准的MTTT相比性能良好。
研究设计与样本
- 研究将Sofia莱姆病试验与Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM试验后接Zeus单价IgM/IgG EIA确认试验进行比较。
主要发现
- 作为一线试验,Sofia与标准Zeus MTTT的阳性符合率为91.4%(95% CI,77.6%-97.0%)。
- 阴性符合率为100%(95% CI,94.0%-100%)。
- 总体符合率为98.3%(95% CI,94.2%-99.4%),κ=0.945,表明几乎完全一致。
临床怎么用
- Sofia莱姆病荧光免疫分析可作为MTTT算法中的一线快速检测选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recently modified 2-tier testing (MTTT) algorithms using 2 enzyme immunoassays (EIAs) as opposed to an EIA followed by immunoblot have been approved by the US Food and Drug Administration (FDA) for the screening and confirmation of Lyme disease. The Quidel Sofia Lyme fluorescent immunoassay is a rapid lateral-flow method that can be performed in real time, permitting on-demand testing. We evaluated the performance of the Sofia assay as a first-tier test in an MTTT algorithm. METHODS: We compared the Sofia Lyme test with the Zeus ELISA Borrelia VlsE1/pepC10 lgG/IgM test, followed by the Zeus monovalent IgM/IgG EIA as the confirmatory test. RESULTS: When used as a first-tier test compared with a standard Zeus MTTT assay, the positive percentage agreement was 91.4%% (95% CI, 77.6%-97.0%). The negative percentage agreement was 100% (95% CI, 94.0%-100%). The overall agreement was 98.3% (95% CI, 94.2%-99.4%). κ = 0.945, indicating "almost perfect agreement." CONCLUSIONS: The Sofia Lyme test performs well compared with an FDA-approved MTTT.
引用
- Lee-Lewandrowski E, Turbett S, Branda JA, et al. Evaluation of the rapid Quidel Sofia Lyme fluorescent immunoassay as a first-tier test in a modified 2-tier testing algorithm for Lyme disease: A comparison with the Zeus ELISA Borrelia VlsE1/pepC10 lgG/IgM assay followed by the Zeus monovalent IgM/IgG confirmatory assay. Am J Clin Pathol. 2023. PMID: 37549102. doi:10.1093/ajcp/aqad094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。